Bicara Therapeutics is a pre-revenue clinical-stage biotech whose R&D spending surged 282% from $12.0M in 2024Q1 to $45.8M in 2026Q2, driving operating losses to -$60.0M and cumulative net losses of -$317.5M over ten quarters.
Price trend, volume and key moving averages
Trailing total returns as of 11/8/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q3 2026Latest Aug 11, 2026 | -$0.82-0.0% vs -$0.82 | — vs — |
Q2 2026 May 11, 2026 | -$0.93-45.3% vs -$0.64 | — vs — |
Q2 2026 Mar 26, 2026 | -$0.68+5.6% vs -$0.72 | — vs — |
Q4 2025 Nov 10, 2025 | -$0.67-21.8% vs -$0.55 | — vs — |
BOSTON, Nov. 04, 2026 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors, today announced it awarded an inducement grant on November 2, 2026, to one new employee as a material inducement to employment under Bicara's 2026 Inducement Plan.
BOSTON, Nov. 02, 2026 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors, today announced that it will report third quarter 2026 financial results and business updates before the market opens on Monday, November 9, 2026. Bicara will host a conference call to discuss the financial results and business updates at 8:30 a.m. ET the same day. Individuals may register for the conference call by clicking the link here. Once registered, participants will receive dial-in details and a unique PIN that will allow them to access the call. To access the live webcast, please visit the “Events & Presentations” section within the Investors page on the Bicara website. A replay of the webcast will be available for 30 days following the event.
Bicara Therapeutics (NASDAQ: BCAX - Get Free Report)'s stock had its "buy" rating reaffirmed by research analysts at BTIG Research in a research report issued on Monday, Benzinga reports. They currently have a $39.00 target price on the stock. BTIG Research's target price indicates a potential upside of 125.10% from the stock's previous close. A number
BOSTON, Aug. 14, 2026 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors, today announced that, effective August 12, 2026, it awarded an inducement grant to Jennifer Larson under Bicara's 2026 Inducement Plan as a material inducement to her commencement of employment as Bicara's Chief Financial Officer. Ms. Larson received a non-qualified stock option to purchase 285,000 shares of Bicara's common stock, par value $0.0001 per share, with an exercise price of $24.63 per share, equal to the closing price of Bicara's common stock as reported by Nasdaq on August 12, 2026.
Benchmark BCAX against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Bicara Therapeutics Inc. Common Stock (BCAX)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $8.65 | $568.34M | -3.17 | — | — | -41.49% | — | |
| $30.53 | $6.3B | -11.66 | — | -7585.86% | -69.59% | — | |
| $59.83 | $9.16B | 21.31 | 87.32% | 55.22% | 72.3% | — | |
| $14.41 | $5B | -15.62 | — | — | -80.43% | — | |
| $131.73 | $10.84B | -37.73 | -16.72% | -341.87% | -22.39% | — | |
| $2.33 | $148.1M | -10.15 | 0.78% | -8.7% | -31.27% | — |
Bicara Therapeutics Inc. Common Stock (BCAX) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
Bicara Therapeutics Inc. Common Stock (BCAX) SEC filings — annual & quarterly reports (10-K, 10-Q)
Aug 11, 2026·SEC
Jul 28, 2026·SEC
Jun 10, 2026·SEC
Get notified when BCAX posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Bicara Therapeutics Inc. Common Stock (BCAX) stock FAQ — growth, dividends, profitability & financials explained
No. Bicara Therapeutics Inc. Common Stock (BCAX) reported a net loss of $185.4M over the trailing twelve months.
Bicara Therapeutics Inc. Common Stock (BCAX) had a return on equity (ROE) of -41.5% over the trailing twelve months. A negative ROE means the company lost money over the period.
Bicara Therapeutics Inc. Common Stock (BCAX) had negative free cash flow of $135.2M over the trailing twelve months.
